Medicinal composition containing rotundine for anayesia and giving up drug-taking

A technology of composition and medicine, applied in the field of pharmaceutical composition containing rotundine

Inactive Publication Date: 2004-03-24
INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A +1
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the compound prescription of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing rotundine for anayesia and giving up drug-taking

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1. Oxycodone / rotundine tablet——wet granulation tablet pressing

[0045] Oxycodone Hydrochloride 5.046g

[0046] Rotundine 50.136g

[0047] Lactose 50.140g

[0048] Sodium carboxymethyl starch 2.100g

[0049] 10% PVP K 30 Proper amount of ethanol solution

[0050] Magnesium stearate 1.010g

[0051] Makes 1000 pieces

[0052] Preparation process: all components are passed through a 80-mesh sieve, the prescription amount of oxycodone hydrochloride, rotundine, and lactose are mixed with a suitable method, and 10% PVP K is added 30 Appropriate amount of ethanol solution, make soft material, granulate with 18 mesh sieve, dry in 50°C drying oven for 30 minutes, granulate with 16 mesh sieve, add the prescribed amount of carboxymethyl starch sodium and magnesium stearate, use suitable Methods Mix well, press the above mixture into tablets of appropriate weight with a tablet machine, and all indicators should meet the requirements of the Chinese Pharmacopoeia...

Embodiment 2

[0053] Example 2, Oxycodone / Rotondine Tablets——Wet Granulation Tablet Compression

[0054] Oxycodone Hydrochloride 5.027g

[0055] Rotundine 30.254g

[0056] Microcrystalline Cellulose 100.180g

[0057] Pregelatinized starch 70.100g

[0058] 20% PVP K 30 Aqueous solution

[0059] Magnesium stearate 2.010g

[0060] Makes 1000 pieces

[0061] Preparation process: all components are passed through a 80-mesh sieve, the prescription amount of oxycodone hydrochloride, rotundine, microcrystalline cellulose, and pregelatinized starch are mixed with a suitable method, and 20% PVP K is added 30 Appropriate amount of aqueous solution, made of soft material, granulated with 18 mesh sieve, dried in a drying oven at 50°C for 50 minutes, granulated with 16 mesh sieve, added magnesium stearate, mixed evenly with a suitable method, and the above The mixture is compressed into tablets of appropriate weight, and all indicators should meet the requirements of the Chinese Pharmacopoeia ...

Embodiment 3

[0062] Embodiment 3, Oxycodone / Rotondine Tablets——Direct Tablet Compression

[0063] Oxycodone Hydrochloride 5.101g

[0064] Rotundine 40.354g

[0065] Microcrystalline Cellulose 100.180g

[0066] Magnesium stearate 3.043g

[0067] Micronized silica gel 1.025g

[0068] Makes 1000 pieces

[0069] Preparation process: Mix the components of the prescription amount evenly, and press into tablets with a φ8mm die. All indicators should meet the requirements of the Chinese Pharmacopoeia on tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a medicine composition for stopping pain and/or stopping drugs, it contains opium receptor complete excitant or opium receptor complete excitant with analgetic effective dose and rotundine with analgetic effective dose. Said medicine composition has strong analgetic effect and its addiction side effect is less.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing rotundine for analgesia and detoxification. Background technique [0002] Rotundine is the L-body of tetrahydropalmatine (L-tetrahydropalmatine, L-THP). . It is well absorbed orally, and its analgesic effect is much weaker than opioids, but stronger than antipyretic analgesics. Take 100-200mg orally, take effect within 10-30 minutes, and have an effective time of 2-5 hours. It is mostly used for chronic persistent dull pain. After years of research, Professor Jin Guozhang found that rotundine is a selective DA 2 Receptor antagonist, it can not only inhibit pain transmission at the level of spinal cord and spinal cord, promote the release of central endogenous opioid peptides, play an analgesic effect, but also effectively inhibit the opioid demand and mental dependence of addicted animals Sex, reduce withdrawal syndrome. [0003] Oxycodone (Oxycodone) is a complete opioid receptor ag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4375A61K31/485A61P25/04A61P25/36
Inventor 宫泽辉秦伯益肖文彬
Owner INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap